Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T436/00—Chemistry: analytical and immunological testing
  • Y10T436/20—Oxygen containing
  • Y10T436/203332—Hydroxyl containing

Definitions

• the invention concerns a process for the production of a hybridoma and a monoclonal antibody obtained therefrom, able to recognize one epitope present on more than one antigen.
• the invention relates to a process for the production of a hybridoma and a monoclonal antibody, or fragments thereof, able to recognize more than one vitamin D metabolites, namely 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
• Vitamin D is the generic term used to designate vitamin D 2 or ergocalciferol and vitamin D 3 or cholecalciferol. Humans naturally produce vitamin D 3 when the skin is exposed to ultraviolet sun rays. Vitamin D 3 is transferred to the liver, where it is metabolised into 25-hydroxyvitamin D 3 , which is the main form of vitamin D circulating in the body. Since the nineteenth century, vitamin D 2 has been available orally through food in order to compensate for a lack of vitamin D 3 for example among people who are hardly exposed to sunlight. The oral consumption of vitamin D 2 has become increasingly important over recent centuries. In fact, it is currently known that vitamin D has a primary role in the body for calcium binding, and mineralization of bones. It also plays a significant role in various metabolic pathways.
• the 25-hydroxyvitamin D, and particularly 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 are the forms of vitamin D which are most easily accumulated in the body. These two precursors can be converted by the kidneys to form 1 ⁇ ,25-dihydroxyvitamin D, which is the biologically active form.
• 1,25-dihydroxyvitamin D relates to the active forms of vitamin D (also known as D hormones) which have a hydroxyl grouping in positions 1 and 25 of the formula (A) and (B). More than fifty or so different metabolites of vitamin D have been discovered to date. Among these are 24,25-dihydroxyvitamin D and 25,26-dihydroxyvitamin D.
• immunological methods involve the use of polyclonal antibodies, or monoclonal antibodies.
• Polyclonal antibodies are known from a long time.
• animals such as rabbits for instance
• the immunisation has to be done repeatedly with such purified preparation.
• this leads to the production of a mixture of antibodies, this mixture randomly binding more than one antigen, thus leading to unspecific measurement.
• a first issue is the life span of the host animal, Frequently, multiple animals needed to be immunised because of biological variability, Some animals being the source of the most specific antisera have to be selected and the death of said animals lead to the end of the production of the desired antibodies, until next immunisation of animals.
• the antiserum reactivity is also a concern because the desired antibody is only a fraction of the total antibodies in the serum, which is itself a too heterogenic mixture.
• the technique suffers from batch-to-batch variability.
• the production of polyclonal antibodies is a quick and inexpensive technique which has been and is still widely used in immunology.
• the latter disclose a process to produce polyclonal antibodies against 25-hydroxyvitamin D, which includes steps of immunising an animal with a conjugate which contains 25-hydroxyvitamin D 3 or 25-hydroxyvitamin D 2 as a hapten, isolating the serum or plasma of this animal and purifying the antibodies contained in the serum or the plasma by immunosorption on a complementary matrix, which includes 25-hydroxyvitamin D 2 when the hapten is 25-hydroxyvitamin D 3 or which includes 25-hydroxyvitamin D 3 when the hapten is 25-hydroxyvitamin D 2 , EAH-Sepharose has been used as the preferred material for the immunosorption matrix.
• monoclonal antibodies can also be used.
• the Kohler and Milstein's invention dated 1975 opened a totally new field in immunology through a technique involving the fusion, in the presence of polyethylene glycol, of a myeloma cell rendered drug sensitive through a mutation in gene HGPRT with immune spleen B cells from a host animal immunised with the antigen of interest.
• Hybridoma cells survive and may be cultured in an appropriate medium (HAT) and rendered immortal. Because each hybridoma descends from one B cell, it makes copies of only one monoclonal antibody.
• the hybridoma that produces the antibody of interest is grown in culture to produce large amounts of monoclonal antibody, which are then isolated for further use. It is worth noting that monoclonal antibody is known to be highly specific antibodies against one epitope.
• the normal production scheme of a monoclonal antibody directed against one specific antigen includes the use of one hapten, the immunisation of one animal (generally a mouse), that after fusion between spleen cell and myeloma cell, one hybridoma is produced, and this latter may be cultured and immortalized to produce one monoclonal antibody specifically directed against a single epitope on a single antigen.
• WO 03/104820 discloses the quantification of vitamins A and D 3 in fluid samples.
• a monoclonal antibody against vitamin A is produced using standard procedures from vitamin A-KLH conjugate (i.e. the hapten is vitamin A).
• a monoclonal antibody against vitamin D 3 is produced from vitamin D 3 -KLH conjugate (i.e. the hapten is vitamin D 3 ).
• two tests have to be performed to obtain the amount of both vitamins in the fluid samples.
• a given hybridoma produces a given type of monoclonal antibody, i.e. in practice several molecules of the same structure, in the present text, when speaking about the invention, one will use “monoclonal antibody” to designate the production of monoclonal antibody from a single hybridoma, and “monoclonal antibodies” to designate the production of monoclonal antibody from different hybridomas.
• vitamin D must be understood within the context of the present document as including the forms of vitamin D 2 and vitamin D 3 with the following formula (A) and (B):
• 25-hydroxyvitamin D indicates the vitamin D metabolites which are hydroxylated at position 25 of the formula (A) and (B), namely 25-hydroxyvitamin D 2 as well as 25-hydroxyvitamin D 3 .
• 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 are particularly relevant forms of vitamin D when used for diagnostic purposes.
• the vitamin D metabolites are not immunogen as such.
• the chemical activation of the components resulting from the metabolism of vitamin D as well as their binding to carrier proteins or linked groups is significant. Therefore, to ensure successful immunisation, it is vital to prepare a conjugate which may contain a metabolite of vitamin D or a derivative thereof as a hapten.
• a hapten must be understood by a person skilled in the art as a substance which is not immunogenic in itself, but which, by coupling with a carrier protein, is revealed in a form against which antibodies can be generated.
• Carrier proteins for the production of conjugates of haptens, i.e. immunogens are known to those of ordinary skill in the art.
• carrier protein refers to a protein which transports a specific substance or a group of substances though the cellular membrane, in extra-cellular fluids or in an intracellular compartment.
• position 3 of the structures such as represented in formula (A) and (B) is, in principle, suitable for the activation and coupling of the carrier proteins.
• the vitamin D metabolites are believed to bind via position 3 (see WO 2007/039194; Kobayashi and al. “Production and specificity of antisera raised against 25-hydroxyvitamin D 3 -[C-3]-bovine serum albumin conjugates”, Steroids 1992, 57(10), pp. 488-493).
• the present invention relates to a process for the production of a hybridoma, and of a monoclonal antibody, or fragments thereof, able to recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 , comprising the following steps:
• n is an integer between 0 and 3;
• R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are independently hydrogen or a C 1-4 alkyl;
• R 12 and R 13 are a C 1-4 alkyl
• R is a hydrogen or a substituent selected from the group consisting of a group of acyl, benzyl, alkyl, aryl, alkyl ether, dimethoxytrityl, methoxytrityl, tetrahydropyranyl, triphenylmethyl groups, and a silyl derivative;
• the present process allows to produce a monoclonal antibody able to bind or recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 (two different molecules) from a hybridoma obtained by immunisation with a single hapten renders immunogenic, i.e. with a single conjugate.
• This is a totally unexpected result which could not be suggested by prior art.
• a monoclonal antibody specifically binds one antigen which is similar to the hapten used.
• the present invention surprisingly discloses a monoclonal antibody binding two different antigens, said monoclonal antibody being produced by a hybridoma provided by immunisation with a single hapten of general formula (I).
• the hapten of general formula (I) may be in the form of a carboxylate salt.
• Organic or inorganic salts may be convenient. Therefore, the salts used can be, for example, sodium, potassium or ammonium salts.
• the hapten of general formula (I) may be a derivative in which the carboxylic acid function may be protected to form an ester, amide or oxazoline.
• the ester may be an alkyl-, aryl-, benzylic-, thio-, séleno-, silyl- or ortho-ester.
• C 1-4 alkyl refers to a hydrocarbon radical having the formula C m H 2m+1 in which m is an integer between 1 and 4.
• C 1-4 alkyl refers to methyl, ethyl, n-propyl, i-propryl, n-butyl, i-butyl, s-butyl and t-butyl radical.
• acyl refers to a radical of formula T 1 C(O)— in which T 1 is a substituent alkyl or aryl.
• benzyl refers to a radical of formula T 2 CH 2 — in which T 2 is an aryl group.
• alkyl ether refers to a radical of formula T 3 OT 4 - in which T 3 is an alkyl, an aryl or a benzyl and T 4 a hydrocarbon chain of formula —(CH 2 ) p — in which p is an integer between 1 and 10.
• diimethoxytrityl refers to the radical bis-(4-methoxyphenyl)phenylmethyl.
• methoxytrityl refers to the radical 4-methoxyphenyl)diphenylmethyl.
• aryl refers to an aromatic hydrocarbon, polyunsaturated group, with one or more fused rings (for example napthyl) or covalently bound, generally containing between 6 and 10 carbon atoms, in which at least one cycle is aromatic.
• the rings can be substituted.
• Non-exhaustive examples include phenyl, napthyl, anthracyl and biphenyl groups.
• substituted indicates that one or more hydrogens of the atom indicated in the expression using “substituted” is replaced with a selection from the indicated group, subject to the valency of the atom(s) indicated not exceeding the normal valency of the same, and that the substitution results in a chemically stable compound, namely a compound sufficiently robust to survive in a clearly identifiable form and to an acceptable degree of purity from the reaction mixture.
• Substituents can be selected, but not limited to, from the group consisting of alkyl, aryl, cycloalkyl, halide, hydroxyl, nitro, amido, carboxy, amino and cyano groups.
• the term “nitro” refers to the group —NO 2 .
• the term “cyano” refers to the group —CN.
• the term “hydroxyl” refers to the group —OH.
• the term “amido” refers to the group —C(O)—NH—.
• the term “carboxy” refers to the group —C(O)O—.
• the term “halide” refers to the chloride, fluoride, bromide and iodide radicals.
• the term “amino” refers to the radical of a trivalent nitrogen atom substituted or not.
• cycloalkyl refers to a cyclic alkyl group including all the hydrocarbon groups containing one or two rings, including monocyclic or bicyclic groups.
• the cycloalkyls include at least three carbon atoms in the cycle, preferably between 3 and 10 carbon atoms and can be optionally substituted.
• alkyl refers to a radical hydrocarbon of formula C m H 2m+1 in which m is an integer greater than 1.
• the alkyl groups of the present invention include between 1 and 10 carbon atoms.
• C 1-10 alkyl refers but is not limited to a radical methyl, ethyl, n-propyl, i-propyl, n-butyl, butyl, s-butyl, t-butyl, 1-pentyl, 2-pentyl, 3-pentyl, i-pentyl, neo-pentyl, t-pentyl, 1-hexyl, 2-hexyl, 3-hexyl, 1-methyl-1-ethyl-n-pentyl, 1,1,2-tri-methyl-n-propyl, 1,2,2-trimethyl-npropyl, 3,3-dimethyl-n-butyl, 1-heptyle, 2-heptyle, 1-ethyl-1,2-dimethyl-n-propyl, 1-ethyl-2,2-dimethyl-n-propyl, 1-octyle, 3-octyle, 4-methyl-3-n-h
• the alkyl group may be substituted.
• tetrahydropyranyl refers to a radical of 2-tetrahydropyrane.
• triphenylmethyl refers to a radical methyl substituted by three aryl groups, preferably phenyl.
• sil derivative refers to a radical of formula T 5 T 6 T 7 Si— in which T 5 , T 6 , T 7 are independently an alkyl, aryl, alkoxy and aryloxy.
• alkoxy refers to a radical of formula —OT 8 in which T 8 is an alkyl substituted or not.
• aryloxy refers to a radical of formula —OT 9 in which T 9 is an aryl substituted or not.
• Said hapten may be rendered immunogen by a covalent coupling with an immunogenic carrier protein, by encapsulation in the liposomes, by anchorage in the liposomes, by coupling of said hapten with a polymer, by induction with a biopolymer, or by coupling with a multiple antigenic peptide.
• immunogenic carrier protein by encapsulation in the liposomes, by anchorage in the liposomes, by coupling of said hapten with a polymer, by induction with a biopolymer, or by coupling with a multiple antigenic peptide.
• immunogenic carrier protein by encapsulation in the liposomes, by anchorage in the liposomes, by coupling of said hapten with a polymer, by induction with a biopolymer, or by coupling with a multiple antigenic peptide.
• immunogenic carrier protein by encapsulation in the liposomes, by anchorage in the liposomes, by coupling of said hap
• said carrier protein may be BSA (bovine serum albumin), ovalbumin, HSA (human albumin serum), THY (thyroglobulin), KLH (keyhole limpet hemocyanine), cBSA (bovine cationic albumin), ⁇ -galactosidase or CCH (Concholepas hemocyanine).
• BSA bovine serum albumin
• HSA human albumin serum
• THY thyroglobulin
• KLH keyhole limpet hemocyanine
• cBSA bivine cationic albumin
• ⁇ -galactosidase or CCH Concholepas hemocyanine
• said polymer When said hapten is bonded to a polymer, said polymer may be a synthetic, natural or modified natural polymer. Therefore, the synthetic polymer may be, but not limited to, for example poly-L-lysine or agarose. Alternatively, the natural polymer ma y be, but not limited to, dextrane. Alternatively, the modified natural polymer may be, but not limited to, carboxymethyl cellulose.
• said hapten may be bonded to a multiple antigenic peptide.
• Said multiple antigenic peptides may be a polylysine core to which 2 to 16 copies of a synthetic peptide are bonded.
• said hapten is rendered immunogenic by a covalent coupling with a carrier protein.
• the KLH and BSA may be particularly effective carrier proteins for the process and use of the present invention.
• the coupling between the hapten and the carrier protein may be performed via the carboxylic acid function of the hapten.
• the hapten may be a derivative of general formula (I) in which n is equal to 0.
• said hapten may be the derivative of general formula (I), in which n is equal to 0 and in which R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are respectively hydrogen; R 12 and R 13 are respectively methyl group.
• the name of such hapten according to the IUPAC standard is the (2S)-2-((7aR, E)-4-((Z)-2-(S)-5-hydroxy-2-methylenecyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)propanoic acid.
• This compound can also be named acid 23,24,25,26,27-pentanor-9,10-secocholesta-5,7,10(19)-trien-3 ⁇ -ol-22-oic, the CAS number of which is 99518-38-4.
• the hapten may be a derivative of general formula (I) in which n is equal to 1.
• said hapten may be the derivative of general formula (I) in which n is equal to 1 and in which R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are respectively hydrogen; R 12 and R 13 are respectively methyl group.
• the name of such hapten according to the IUPAC standard is the acid (R)-3-((1R,3aS,7aR,E)-4-((Z)-2-((S)-5-hydroxy-2-methylenecyclohexylidene)-ethylidene)-7a-methyloctahydro-1H-inden-1-yl)butanoic.
• This compound can also be named acid 24,25,26,27-tetranor-9,10-secocholesta-5,7,10(19)-trien-3 ⁇ -ol-23-oic, the CAS number of which is 76794-34-8.
• the hapten may be a derivative of general formula (I) in which n is equal to 2.
• said hapten may be the derivative of general formula (I) in which n is equal to 2 and in which R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are respectively hydrogen; R 12 and R 13 are respectively methyl group.
• the hapten may be a derivative of general formula (I) in which n is equal to 3.
• said hapten may be the derivative of general formula (I) in which n is equal to 3 and in which R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are respectively hydrogen; R 12 and R 13 are respectively methyl group.
• the name of such hapten according to the IUPAC standard is the acid (R)-5-((1R,3aS,7aR,E)-4-((Z)-2-((S)-5-hydroxy-2-methylenecyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)-hexanoic.
• This compound can also be named acid 26,27-bisnor-9,10-secocholesta-5,7,10(19)-trien-3 ⁇ -ol-25-oic.
• the hybridoma produced following the fusion of the myeloma with the B cells of the animal can be chosen in the group consisting of the hybridomas deposited in the BCCM/LMBP (BCCM/LMBP® Belgian Coordinated Collections of Microorganisms—Department of Biomedical Molecular Biology—Ghent, Belgium) on Sep. 21, 2009 under deposit numbers LMBP 7011CB, LMBP 7012CB and LMBP 7013CB, and hybridomas deposited in the BCCM/LMBP on Mar. 9, 2010 under deposit numbers LMBP 7205CB and LMBP 7204CB.
• the animal used for the experiments may be a rabbit, mouse, hamster, rat, and others.
• Each of the monoclonal antibody produced by a single hybridoma of the present process is able to recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
• the recognition of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 may be simultaneous.
• the term “simultaneous” means that a monoclonal antibody produced by the process of the present invention is able to bind or recognize both 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 when both antigens are present in the same sample. Therefore, the recognition percentage of the 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 may be between 70 and 110%.
• hybridomas each able to produce a monoclonal antibody or fragments thereof able to recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 are provided.
• a hybridoma may be obtainable by the steps of a) and b) of the present process.
• the hybridoma can be chosen in the group consisting of the hybridomas deposited in the BCCM/LMBP (Belgian Coordinated Collections of Microorganisms—Department of Biomedical Molecular Biology—Ghent, Belgium) on Sep. 21, 2009 under deposit numbers LMBP 7011CB, LMBP 7012CB and LMBP 7013CB, and hybridomas deposited in the BCCM/LMBP on Mar.
• BCCM/LMBP Belgian Coordinated Collections of Microorganisms—Department of Biomedical Molecular Biology—Ghent, Belgium
• each of these hybridomas is able to produce a monoclonal antibody, or fragments thereof, able to recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
• the recognition of the 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 by said monoclonal antibody, produced by a hybridoma according to the invention, may be simultaneous when the sample tested contains both 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
• the monoclonal antibody, or the fragments thereof, produced by the hybridoma according to the invention may reveal a recognition percentage of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 ranging from 70 to 110%.
• Said hybridoma may be used in the manufacturing of a diagnostic device able to recognize and quantify 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 in a sample or samples to be tested or may be used for the production of monoclonal antibody or fragments thereof able to recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
• Said hybridoma may be genetically engineered for enhancing the secretion of monoclonal antibody produced therefrom, i.e.
• plasmid or DNA sequence may be added to the DNA sequence of the hybridoma to form a genetically engineered hybridoma which can be used for producing monoclonal antibody able to recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
• monoclonal antibody or fragments thereof is provided.
• Said monoclonal antibody or fragments thereof is able to recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 . Therefore, monoclonal antibody or fragments thereof against the two antigens 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 are provided.
• said monoclonal antibody may be obtainable by the process of the present invention.
• said monoclonal antibody or fragments thereof can be produced from a hybridoma selected from the group consisting of the hybridomas deposited in the BCCM/LMBP under deposit numbers LMBP 7011CB, LMBP 7012CB and LMBP 7013CB, and hybridomas deposited in the BCCM/LMBP on Mar. 9, 2010 under deposit numbers LMBP 7205CB and LMBP 7204CB.
• a hybridoma selected from the group consisting of the hybridomas deposited in the BCCM/LMBP under deposit numbers LMBP 7011CB, LMBP 7012CB and LMBP 7013CB, and hybridomas deposited in the BCCM/LMBP on Mar. 9, 2010 under deposit numbers LMBP 7205CB and LMBP 7204CB.
• Each of these hybridomas is able to produce a monoclonal antibody, or fragments thereof, able to recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
• the invention concerns the use of a hapten consisting of a compound of general formula (I), or a salt thereof, or a derivative thereof in which the carboxylic acid function is protected to form an ester, amide or oxazoline,
• n is an integer between 0 and 3;
• R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are independently hydrogen or a C 1-4 alkyl;
• R 12 and R 13 are a C 1-4 alkyl
• R is a hydrogen or a substituent selected from the group consisting of an acyl, benzyl, alkyl, aryl, alkyl ether, dimethoxytrityl, methoxytrityl, tetrahydropyranyle, triphenylmethyl group, and a silyl derivative; said hapten rendered immunogenic;
• the hapten consisting of a compound of general formula (I) may be used for the production of recombinants monoclonal antibody fragments able to recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
• Said hapten may be used for the production of hybridoma according to steps a) and b) of the process of the present invention defined above.
• Said hapten may be used for the production of a monoclonal antibody according to the process of the present invention defined above.
• Said hapten may be rendered immunogenic by a covalent coupling with an immunogenic carrier protein, by encapsulation in the liposomes, by anchorage in the liposomes, by coupling of said hapten with a polymer, by induction with a biopolymer, or by coupling with a multiple antigenic peptide.
• said carrier protein may be the BSA (bovine serum albumin), ovalbumin, HSA (human serum albumin), THY (thyroglobulin), the KLH (Keyhole limpet hemocyanin), cBSA (cationic bovine serum albumin), ⁇ -galactosidase or CCH (Concholepas hemocyanine).
• BSA bovine serum albumin
• HSA human serum albumin
• THY thyroglobulin
• KLH Keyhole limpet hemocyanin
• cBSA cationic bovine serum albumin
• ⁇ -galactosidase or CCH Concholepas hemocyanine
• said polymer When said hapten is coupled to a polymer, said polymer may be a synthetic, natural or modified natural polymer. Therefore, the synthetic polymer may be, but not limited to, for example poly-L-lysine or agarose. Alternatively, the natural polymer may be, but not limited to, dextrane. Alternatively, the modified natural polymer may be, but not limited to, carboxymethyl cellulose.
• said hapten may be rendered immunogenic by induction with a biopolymer.
• the process is described in the publication Basalp and al. “Immunogenic Cu 2+ -induced Biopolymer systems comprising a steroid hormone, protein antigen, and synthetic polyelectrolytes” Hybridoma and Hybridomics, 2002, 21(1), 45-51, attached hereto in the reference.
• said hapten may be coupled to a multiple antigenic peptide.
• Said multiple antigenic peptides may be a polylysine core where 2 to 16 copies of a synthetic peptide are coupled.
• said hapten is rendered immunogenic by a covalent bond with a carrier protein.
• the KLH and BSA can be particularly effective carrier proteins for the process and the use of the present invention.
• the coupling between the hapten and carrier protein may be performed via the carboxylic acid function of the hapten.
• the hapten used for the production of a hybridoma and monoclonal antibody obtained therefrom and able to recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 may be a compound of formula (I) in which n is equal to 0.
• said hapten may be the acid (2S)-2-((7aR, E)-4-((Z)-2-((S)-5-hydroxy-2-methylenecyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)propanoic, namely the compound of formula (I) in which n is equal to 0; R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are respectively hydrogen; R 12 and R 13 are respectively methyl groups.
• the hapten used for the production of a hybridoma and monoclonal antibody obtained therefrom and able to recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 may be the compound of formula (I) in which n is equal to 1.
• the hapten may be the acid (R)-3-((1R,3aS,7aR,E)-4-((Z)-2-((S)-5-hydroxy-2-methylenecyclo-hexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)butanoic, namely the compound of formula (I) in which n is equal to 1; R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are respectively hydrogen; R 12 and R 13 are respectively methyl groups.
• the hapten used for the production of a hybridoma and monoclonal antibody obtained therefrom and able to recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 may be the compound of formula (I) in which n is equal to 2.
• the hapten may be the acid (R)-4-((1R,3aS,7aR,E)-4-((Z)-2-((S)-5-hydroxy-2-methylenecyclohexylidene)-ethylidene)-7a-methyloctahydro-1H-inden-1-yl)pentanoic, namely the compound of formula (I) in which n is equal to 2; R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are respectively hydrogen; R 12 and R 13 are respectively methyl groups.
• the hapten used for the production of a hybridoma and monoclonal antibody obtained therefrom and able to recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 may be the compound of formula (I) in which n is equal to 3.
• the hapten may be the acid (R)-5-((1R,3aS,7aR,E)-4-((Z)-2-((S)-5-hydroxy-2-methylenecyclohexylidene)-ethylidene)-7a-methyloctahydro-1H-inden-1-yl)hexanoic, namely the compound of formula (I) in which n is equal to 3; R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are respectively hydrogen; R 12 and R 13 are respectively methyl groups.
• the recognition of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 by said monoclonal antibody, or the fragments thereof may be simultaneous when both antigens are present in the same sample.
• the recognition percentage of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 , by said monoclonal antibody or the fragments thereof may be between 70 and 110%.
• the hapten and/or monoclonal antibody, or the fragments thereof, according to the invention can be used in the manufacturing of a diagnostic device able to recognize and quantify 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 in a sample or samples to be tested.
• the hapten being a compound of general formula (I) such as defined above, may be used in the manufacturing of a diagnostic device able to recognize and quantify 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 in a sample to be tested.
• the recognition of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 by said monoclonal antibody may be simultaneous when both antigens are in the same sample.
• the recognition percentage of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 by said monoclonal antibody may be between 70 and 110%.
• a diagnostic device likely to allow the recognition and/or quantification of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 in a sample to be tested.
• the term “diagnostic device” as used herein also refers to a kit for the recognition and/or quantification of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 in a sample.
• the sample may be a human or animal sample.
• Diagnostic device encompasses testing device for animal research.
• Said diagnostic device includes a monoclonal antibody or fragments thereof able to recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
• the monoclonal antibody or the fragments thereof of said diagnostic device may be produced, according to the present invention, from a hybridoma selected from the group consisting of the hybridomas deposited in the BCCM/LMBP under deposit numbers LMBP 7011CB, LMBP 7012CB, LMBP 7013CB, LMBP 7204CB and LMBP 7205CB.
• the recognition of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 , by said monoclonal antibody or fragments thereof, may be simultaneous.
• the recognition percentage of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 by said monoclonal antibody or fragments thereof, may be between 70 and 110%.
• Said sample to be tested may be a biological sample from human or animal origin.
• the diagnostic device may also include a sample of the compound of formula (I), or a salt thereof, or a derivative thereof in which the carboxylic acid function is protected to form an ester, amide or oxazoline,
• n is an integer between 0 and 3;
• R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are independently hydrogen or a C 1-4 alkyl;
• R 12 and R 13 are a C 1-4 alkyl
• R is a hydrogen or a substituent selected from the group consisting of an acyl, benzyl, alkyl, aryl, alkyl ether, dimethoxytrityl, methoxytrityl, tetrahydropyranyle, triphenylmethyl group, and a silyl derivative.
• the diagnostic device may include a sample of the compound of formula (I) in which n is an integer equal to 0; R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are respectively hydrogen; R 12 and R 13 are respectively methyl groups.
• the diagnostic device may include a sample of the compound of formula (I) in which n is an integer equal to 1; R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are respectively hydrogen: R 12 and R 13 are respectively methyl groups.
• the diagnostic device may include a sample of the compound of formula (I) in which n is an integer equal to 2; R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are respectively hydrogen; R 12 and R 13 are respectively methyl groups.
• the diagnostic device may include a sample of the compound of formula (I) in which n is an integer equal to 3; R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are respectively hydrogen; R 12 and R 13 are respectively methyl groups.
• the diagnostic device may also include means of expression of a representative signal of the presence of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 in a sample to be tested.
• Said means of expression of a signal may be the tracer of formula (II),
• n is an integer between 0 and 3;
• R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are independently hydrogen or a C 1-4 alkyl;
• R 12 and R 13 are a C 1-4 alkyl
• R is a hydrogen or a substituent selected from the group consisting of an acyl, benzyl, alkyl, aryl, alkyl ether, dimethoxytrityl, methoxytrityl, tetrahydropyranyle, triphenylmethyl group, and a silylic derivative;
• R 16 is the HRP protein (horseradish peroxidase), the alkaline phosphatase protein, the POD protein (peroxidase) or a group of formula (III) or (IV),
• I 125 refers to a radio-isotope of the iodine atom.
• the group (III) is bonded to the compound of formula (II) by its “amino” NH function.
• the group (IV) is bonded to the compound (II) by its “amido” C(O)NH— function.
• R 16 may be 125 I-labeled histamine, 125 I-labeled histidine, 125 I-labeled tyrosine, 125 I-labeled methyl tyrosinate, a fluorescent group, a chemiluminescent group or a group of formula (V)
• Z is a linker and W is a functional group able to bind with a carbonyl group.
• Z may be a C 1-20 alkyl substituted or not.
• W may be amino, amido, hydroxyl, or hydrazine moiety.
• said tracer may be of formula (II),
• n is an integer between 0 and 3;
• R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are hydrogen;
• R 12 and R 13 are a methyl group;
• R 16 is a group of formula (III).
• the diagnostic device may contain a sample of a tracer of formula (II) in which n is equal to 0; R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are hydrogen; R 12 and R 13 are a methyl group; R 16 is a group of formula (III).
• said means of expression of a signal is a biosensor.
• biosensor refers to a physicochemical device able to detect a biological sample in a physicochemical, optical, piezoelectric, electrochemical, or electromagnetic manner.
• the biosensor notably includes a related electronic element, or signal processor allowing the handling or display of data, and a detecting element detecting physicochemical changes in the form of signals.
• the monoclonal antibody may be bonded to a support in the biosensor.
• the hapten of general formula (I) as defined above, rendered immunogenic may be used for the production of a hybridoma.
• Said production of a hybridoma may comprise the steps of:
• n is an integer between 0 and 3;
• R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are independently hydrogen or a C 1-4 alkyl
• R 12 and R 13 are a C 1-4 alkyl
• R is a hydrogen or a substituent selected from the group consisting of acyl, benzyl, alkyl, aryl, alkyl ether, dimethoxytrityl, methoxytrityl, tetrahydropyranyle, triphenylmethyl group, and a silyl derivative; and
• a process for producing a monoclonal antibody, or fragments thereof, able to recognize, or directed against, 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 may be provided.
• a significant advantage of the process of the invention is that it allows the simultaneous recognition of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 in a sample, in a simple procedure, which is also easily reproducible. In addition, this process responds to a long-unfulfilled industry need, despite the fact that technology in the field of monoclonal antibodies has been known for several decades.
• the present invention shall be described according to a specific form of execution in which the hapten, used for the immunisation of the animal, is a derivative of formula (I) in which n is an integer equal to 0; R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are hydrogen; R 12 and R 13 are a methyl group.
• This hapten shall be referred to as (H) for the remaining description. It is important to understand that the invention is not limited to this embodiment.
• the hapten may be a derivative of formula (I) in which n is equal to 1, 2 or 3 with substituents unchanged.
• a monoclonal antibody may be effected following the conventional procedure such as described, for example, in Kohler and Milstein, Nature 1975 (256), 495-497 or Eur. J. Immunol. 1976 (6), 511-519.
• myeloid cells are combined with lymphocytic B cells of an immunised animal to obtain hybrid cells, known as a hybridoma, which produce a monoclonal antibody.
• a hapten is bonded to a carrier protein to form an immunogen which shall be capable of inducing immunogenicity.
• the carrier protein thus allows the hapten to gain the ability to trigger an immune reaction.
• the hapten (H) is initially coupled with the bovine serum albumin (BSA) according to the following protocol.
• BSA bovine serum albumin
• an amount of hapten (H) is activated for four hours at ambient temperature by the O—(N-Succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TSTU—Fluka 85972) dissolved in anhydrous dimethylformamide.
• hapten equivalents in solution are added to a BSA equivalent (Calbiochem 12659) diluted in carbonate buffer solution (0.1M; pH 9.4).
• the solution is stirred at ambient temperature for 18 h away from exposure to light.
• the reactional mixture is then dialysed in a saline solution NaCl (9 g/l) for 48 h at 4° C. A fresh saline solution is re-introduced after 24 h.
• the hapten (H) may also be coupled with KLH (Keyhole limpet hemocyanine, Sigma H2133).
• KLH Keyhole limpet hemocyanine, Sigma H2133.
• 20,000 to 500,000 equivalents of hapten in solution are added to a KLH equivalent diluted in the carbonate buffer solution (0.1M; pH 9.4).
• the solution is then stirred at ambient temperature for 18 h and away from exposure to light.
• the reaction mixture is then dialysed in a saline solution NaCl (9 g/l) for 48 h at 4° C. to obtain the desired immunogen.
• a fresh saline solution is re-introduced after 24 h.
• the immunogen (20 ⁇ g in physiological saline solution) was injected subcutaneously in the mice with an additive (50% saline solution/50% additive (vol/vol)) which could be Freund's complete adjuvant (CFA, Difco Laboratories and reference: 263810) or Freund's incomplete adjuvant (IFA, Difco Laboratories and reference: 263910).
• CFA Freund's complete adjuvant
• IFA Freund's incomplete adjuvant
• the adjuvant allows an immune response to be triggered in the body of the animal.
• the serum of each immunised mouse was tested to monitor the serous content in terms of specific antibodies to the injected antigen. As soon as a mouse was considered positive (namely where the percentage binding of the radioactive-marked antigen or enzymatic marker achieved at least 10% when incubated with the mouse serum), it was selected for the cellular fusion carried out in the month following the serum test.
• the animal was euthanized (using CO 2 ), its spleen was extracted and the immunocompetent cells present in the spleen of the animal were retrieved by rubbing the spleen with flat-tipped forceps while perfusing it slowly with 10 ml of medium W/O kept at 37° C., namely a DMEM Dulbecco modified Eagle's Medium (GIBCO 21969) without protein and complemented with 2% (vol/vol) of a mixture 100 ⁇ of penicillin and streptomycin.
• the cells thus sampled were transferred in a Petri dish, then in a sterile conical tube of 15 ml which was then centrifuged. The cell residue was then retrieved to be combined with the myeloid cells.
• the myeloma used for the fusion of mouse splenocytes are NSO myeloma (Sigma ref:85110503), SP2/0-Ag14 (ATCC ref:CRL-1581) or P3X63Ag8.653 (ATCC ref:1580).
• the myeloma were cultivated in a medium including a DMEM base mixture without additional protein of 2% (vol/vol) of a mixture 100 ⁇ of penicillin and streptomycin, 2 to 5% (vol/vol) of glutamine, 2% (vol/vol) of non-essential amino acids (100 ⁇ ), 2% (vol/vol) of sodium pyruvate (100 ⁇ ), 1% (vol/vol) of gentamicine.
• the medium also included 10% (vol/vol) of foetal calf serum.
• the culture was centrifuged in the sterile conical tubes of 50 ml (at 1000 rpm, 10 minutes). The bases were gathered and centrifuged in a tube of 15 ml. Generally speaking, 1 ml of myeloma represents between 1 10 6 and 2 10 8 cells.
• the spleen cells were mixed with the myeloma cells, to form a hybridoma, with a ratio of around 5 to 10 spleen cells for 1 myeloma cell.
• 4.7 ml of NSO myeloma at 3.4 ⁇ 10 6 cells/ml were mixed with 8 ⁇ 10 7 spleen cells.
• the mixture of spleen cells with myeloma cells was centrifuged and the supernatant removed. The cell residue thus obtained was slowly (1 minute) suspended in 1 ml of a polyethylene glycol solution 50%, with the temperature maintained at 37° C. for this operation.
• the polyethylene glycol solution was obtained by dissolving 5 g of polyethylene glycol (Merck, ref: 1.09727.0100) in 5 ml of phosphate buffer 0.1 M at pH 7.4, then adding 5% (vol/vol) of dimethylsulfoxide to the same (Sigma D2650) and sterilising by filtration (0.2 ⁇ m).
• the cell residue thus re-suspended in the PEG solution was diluted at least 10 times, by adding a W/O medium (DMEM without additional protein of 2% (vol/vol) of a mixture 100 ⁇ of penicillin and streptomycin).
• the tube was centrifuged and the cell residue re-suspended in the HAT medium, including a DMEM base mixture without protein with added 2% (vol/vol) of a mixture 100 ⁇ of penicillin and streptomycin, 2 to 5% (vol/vol) of glutamine, 2% (vol/vol) of non-essential amino acids (100 ⁇ ), 2% (vol/vol) of sodium pyruvate (100 ⁇ ), 1% (vol/vol) of gentamicine, 10% (vol/vol) of foetal calf serum, 2% (vol/vol) of hypoxanthine thymidine (50 ⁇ ), 2% (vol/vol) of aminopterine (50 ⁇ ), and finally 2% (vol/vol) of Nutridoma CS (Roche ref: 1363 743).
• the volume of HAT medium added to the cell residue was such that the spreading over the plates of 96 vessels was from 5 10 4 to 10 5 cells per vessel, based on 150 to 200 ⁇ l of medium per vessel.
• the plates were incubated for between 8 to 10 days, at 37° C. and with 5% CO 2 .
• the identification of wells from deep-well plates containing hybridoma producing monoclonal antibody able to recognize 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 was conducted using an RIA (Radio Immuno Assay) method during the homogenous phase, followed by an immuno-precipitation.
• RIA Radio Immuno Assay
• This method consists of incubating a volume (between 50 and 100 ⁇ l) of the culture medium originating from the deep-well plates of the fusion, with a tracer of formula (II) in which n is equal to 0; R, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 14 , R 15 are hydrogen; R 12 and R 13 are a methyl group; R 16 is a group of formula (III). After an incubation period of between 4 and 18 h, the reaction was stopped by the addition of SAC CEL (a cellulose suspension containing anti-mouse antibodies: IDS reference: AASAC4) to the medium.
• SAC CEL a cellulose suspension containing anti-mouse antibodies: IDS reference: AASAC4
• the positive wells are those which contained mouse antibodies specifically for the hapten (H), hence those containing specific hybridoma clones.
• the recognition tests were carried out with solutions of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 at concentrations of 1000 ng/ml.
• the tracer was in solution in a mixture volume/volume: 25% water/25% ethanol/50% phosphate buffer 0.1M pH 7.4 CP (casein peptone: organotechnical reference: 1 9516) 10 g/l.
• the reaction was stopped by immunoprecipitation by adding SAC CEL (cellulose suspension containing anti-mouse antibodies: IDS reference: AASAC4) to the incubation medium.
• Table 1 represents the recognition results of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 for selected hybridoma clones following preselection tests of hybridomas producing hapten-specific monoclonal antibodies.
• the first column represents the numbers of the tested clones, which correspond to the hybridoma deposited as described above.
• the second column corresponds to the percentage of binding of said tracer to the monoclonal antibody produced by the corresponding clone, in the absence of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
• the third column corresponds to the percentage of binding of said tracer to the monoclonal antibody produced by the corresponding clone in the presence of 25-hydroxyvitamin D 2 at a concentration in solution of 1 ⁇ g/ml.
• the fourth column corresponds to the inhibition percentage of corresponding monoclonal antibody in the presence of 25-hydroxyvitamin D 2 at a concentration of 1 ⁇ g/ml.
• This percentage is calculated by deducting from 100% the ratio, multiplied by 100, between the percentage of binding in the presence of 25-hydroxyvitamin D 2 at 1000 ng/ml and the percentage of binding without 25-hydroxyvitamin D 2 .
• the fifth column corresponds to the percentage of binding of said tracer to the monoclonal antibody produced by the corresponding clone in the presence of 25-hydroxyvitamin D 3 at a concentration in solution of 1 ⁇ g/ml.
• the sixth column corresponds to the inhibition percentage of the corresponding monoclonal antibody in the presence of 25-hydroxyvitamin D 3 at a concentration of 1 ⁇ g/ml. This percentage is calculated by deducting from 100% the ratio, multiplied by 100, between the percentage of binding in the presence of 25-hydroxyvitamin D 3 at 1 ⁇ g/ml and the percentage of binding without 25-hydroxyvitamin D 3 .
• the inhibition percentage of the monoclonal antibody produced by the clone LMBP7012CB may exceed 80% vis-à-vis 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
• a test of the simultaneous recognition of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 was conducted on coated tubes.
• the monoclonal antibody was anchored in dry tubes (direct coating) at a concentration of 0.5 ⁇ g/ml.
• the antibody used was produced by the LMBP hybridoma 7013CB.
• 300 ⁇ l of incubation buffer phosphate 50 mM pH7.4 casein peptone 2 g/l of sodium azide 0.5 g/l
• 100 ⁇ l of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 were added to the tubes.
• the solutions were analysed after two hours at ambient temperature.
• a monoclonal antibody is performed by a system of in vitro culture of hybridoma cells for example: in a spinner flask (Wheaton Magna-Flex® Microcarrier Spinner Flasks), or in CELLINE (Integra Bioscience) or any other method of in vitro culture suitable for hybridoma cells.
• the monoclonal antibody can be produced by an in vivo method, such as that featuring ascites, where permitted by law.
• the culture's supernatant originating from the in vitro culture system of hybridoma cells is purified by affinity chromatography on a conventional column of protein A and/or protein G (GE Healthcare), on a STREAMLINE Protein A support (GE Healthcare).
• the diagnostic devices according to the invention can include “enzyme immunoassays” devices (EIA) or “enzyme-linked immunosorbent assays” devices (ELISA), an “immunofluorescence” device (IFA), a radiometric device or “radioimmunoassays” (RIA), a “magnetic separation assays” device (MSA), a “lateral flow assays” device, a “diffusion immunoassays” device, an immuno-precipitation device, an “immunosorbent” or “antigen-down assays” device, an immuno-agglutination device, a “chemilunescence immuno assay (CLIA)” device or also a device using a biosensor.
• EIA enzyme immunoassays
• ELISA enzyme-linked immunosorbent assays
• IFA immunofluorescence
• RIA radiometric device or “radioimmunoassays”
• MSA magnetic separation assays
• Various types of supports can be used: tubes, microtitration plates or blocks.
• the monoclonal antibody or the fragments thereof can be biotinylated to increase the binding or sensitivity to the different supports.
• the monoclonal antibody, or fragments related to the same may be bound directly onto the support. It is also possible to bind an anti-mouse antibody to the support, followed by monoclonal antibody or fragments thereof according to the invention on this initial antibody.
• the monoclonal antibody or fragments thereof should preferably be biotinylated.
• the hapten may be bound to the support.
• a monoclonal antibody according to the invention is added, followed by an anti-HRP secondary antibody.
• the monoclonal antibody or fragments thereof can be used by direct binding to the HRP (horse radish peroxidase) in order to detect the immunogenic bound beforehand onto a support.
• the monoclonal antibody, or the fragments related to the same can be biotinylated.
• the SAv-HRP streptavidin-horse radish peroxidase
• the tracer may be bound to a tyramine marked with iodine 125 for the RIA tests. It may also be used after biotinylation or binding to the HRP with a view to conducting ELISA or CLIA tests. The luminol or tetramethylbenzidine can subsequently be bonded to the HRP.
• test can be performed in open or sealed automatic units.
• the recognition of 25-hydroxyvitamin D 3 and 25-hydroxyvitamin D 2 is simultaneous when using diagnostic devices according to the invention on samples containing 25-hydroxyvitamin D 3 and 25-hydroxyvitamin D 2 .

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Biomedical Technology (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biotechnology (AREA)
• Cell Biology (AREA)
• Microbiology (AREA)
• Food Science & Technology (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Endocrinology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Peptides Or Proteins (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Priority Applications (2)

Applications Claiming Priority (6)

Related Child Applications (1)

Publications (1)

Family

ID=43413460

Family Applications (2)

Family Applications After (1)

Country Status (6)

Cited By (5)

Families Citing this family (8)

Citations (3)

Family Cites Families (7)

• 2010
  • 2010-10-26 US US12/911,924 patent/US20110097733A1/en not_active Abandoned
  • 2010-10-27 BE BE2010/0637A patent/BE1018792A5/fr active
  • 2010-10-27 AU AU2010236056A patent/AU2010236056B2/en not_active Withdrawn - After Issue
  • 2010-10-27 EP EP10189130.7A patent/EP2316854B1/fr not_active Revoked
  • 2010-10-27 WO PCT/EP2010/066271 patent/WO2011051348A1/fr active Application Filing
  • 2010-10-27 JP JP2010240510A patent/JP2011136978A/ja active Pending
• 2015
  • 2015-05-11 US US14/708,594 patent/US9746483B2/en active Active

Patent Citations (3)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events